UITM-CaixaResearch presents promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumors, especially in melanoma
Preliminary data from the first patient trial of the bispecific antibody FS222 indicate a manageable toxicity profile and promising...
